$12.76
+0.01 (+0.08%)
Open$12.77
Previous Close$12.75
Day High$12.99
Day Low$12.65
52W High$69.97
52W Low$10.03
Volume—
Avg Volume564.3K
Market Cap190.97M
P/E Ratio—
EPS$-14.34
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+219.3% upside
Current
$12.76
$12.76
Target
$40.74
$40.74
$28.14
$40.74 avg
$50.62
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 24.82M | 84.57M | 86.26M |
| Net Income | -234,826,373 | -20,699,385 | -25,319,011 |
| Profit Margin | -946.2% | -24.5% | -29.4% |
| EBITDA | -238,326,698 | -24,990,141 | -25,196,528 |
| Free Cash Flow | — | -20,292,095 | -20,848,476 |
| Rev Growth | — | +3.2% | +20.0% |
| Debt/Equity | — | 0.58 | 0.68 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |